Systemic Treatments and Monitoring

When Pyoderma Gangrenosum (PG) is spreading rapidly or covers a large area, doctors must move beyond creams and ointments to systemic treatments—medications that work throughout your entire body to quiet the overactive immune system ^[1]. Because these drugs are powerful, the goal is to find a balance between stopping the skin destruction and minimizing serious side effects ^[2].

The Standard First Steps: Corticosteroids and Cyclosporine

For years, doctors debated whether steroids or other immune-suppressing drugs were better for PG. A landmark clinical trial called the STOP-GAP trial provided the answer. Researchers compared prednisolone (a common oral corticosteroid) to cyclosporine (a different type of immunosuppressant) ^[3].

The trial found that both drugs performed almost identically:

• Healing Rates: About 47% of patients in both groups were completely healed at the six-month mark ^[3].
• Speed: Neither drug was significantly faster at starting the healing process ^[3].
• Recurrence: Among those who healed, about 30% saw the ulcer return, regardless of which drug they took ^[3].

Because the effectiveness is so similar, the choice often depends on which side effects you are better able to manage. Prednisolone is often associated with weight gain, mood changes, and bone thinning over time. Prolonged corticosteroids require monitoring for glucose (blood sugar), blood pressure, bone loss, and other complications, and they must not be stopped abruptly without medical guidance. Cyclosporine requires close monitoring of blood pressure and kidney function ^[4][3].

Biologics: Targeted Therapy

If standard treatments don’t work or if you have other inflammatory conditions, your doctor may suggest a biologic. These are modern, engineered proteins that target specific parts of the immune system ^[5]. Selection is specialist- and comorbidity-dependent, and many uses are off-label for PG.

• Infliximab: This has evidence from a small randomized trial showing early clinical improvement for PG. In one study, nearly half of patients showed a response within just two weeks ^[5]. It is often an option for patients who also have Inflammatory Bowel Disease (IBD), as it can treat both the gut and the skin simultaneously ^[6].
• Adalimumab: This is another biologic supported largely by smaller or observational reports, frequently considered for patients with rheumatoid arthritis or IBD ^[7]. While it has less trial data specifically for PG than infliximab, it is used in practice and offers the convenience of being an injection you can do at home rather than an IV infusion ^[8][9].

Steroid-Sparing Agents: Mycophenolate Mofetil

Because high-dose steroids have many long-term risks, doctors often add a “steroid-sparing” drug like mycophenolate mofetil (MMF) ^[4]. This drug helps keep the immune system calm while your doctor slowly lowers (tapers) your steroid dose. While observational evidence suggests it can take several months for significant improvement, it can be a part of long-term management ^[4]. Critically, Mycophenolate requires prominent pregnancy-prevention and pregnancy-planning measures because of severe fetal risks.

Serious Risks and Monitoring

All systemic PG treatments carry a significant risk: immunosuppression. By turning down the “alarm” in your immune system to save your skin, these drugs also make it harder for your body to fight off actual infections ^[10].

• Infection Risk: Serious infections are a major concern. In the STOP-GAP trial, serious infections were more common in the group taking prednisolone ^[3]. Contact your doctor urgently if you develop a fever, new cough, urinary symptoms, or sudden wound deterioration.
• Monitoring: You will likely need frequent blood tests to check your white blood cell counts, liver enzymes, and kidney markers ^[4].
• Hidden Infections: Before starting biologics, your doctor must screen you for “sleeping” infections like tuberculosis or Hepatitis B, which could reactivate when your immune system is suppressed ^[1].
• Vaccinations: Vaccination timing and avoidance of live vaccines need clinician guidance before and during immunosuppression.

Every person’s journey with PG is different. Your treatment plan should be a conversation about your lifestyle, your other health conditions, and your tolerance for specific risks ^[3].